伊布替尼单药治疗复发/难治性双表达 B 细胞淋巴瘤患者的结局。
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
机构信息
Department of Medicine.
Department of Pharmacy, and.
出版信息
Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401.
Abstract
The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.
摘要
B 细胞受体信号通路在弥漫性大 B 细胞淋巴瘤中呈活跃状态，MYC 和 BCL2 蛋白表达增加。伊布替尼治疗复发性/难治性非生发中心双表达型淋巴瘤患者的总缓解率为 60%。
相似文献
1
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.伊布替尼单药治疗复发/难治性双表达 B 细胞淋巴瘤患者的结局。
Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401.
2
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.依鲁替尼用于日本复发/难治性套细胞淋巴瘤患者的II期研究的最终分析。
J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.
3
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.一项关于阿利西替尼用于复发或难治性B细胞非霍奇金淋巴瘤患者的2期试验。
Leuk Lymphoma. 2017 Sep;58(9):1-2. doi: 10.1080/10428194.2017.1289527. Epub 2017 Feb 20.
4
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.伊布替尼在日本复发或难治性套细胞淋巴瘤患者中的疗效与安全性。
Cancer Sci. 2016 Dec;107(12):1785-1790. doi: 10.1111/cas.13076. Epub 2016 Nov 25.
5
Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.伊布替尼是治疗B细胞原淋巴细胞白血病的一种有效疗法。
Br J Haematol. 2017 Nov;179(3):501-503. doi: 10.1111/bjh.14224. Epub 2016 Jul 8.
6
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.
7
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.依鲁替尼是一种治疗累及中枢神经系统的系统性套细胞淋巴瘤的安全有效的疗法——来自英国的一项多中心病例系列研究。
Br J Haematol. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16.
8
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.伊布替尼揭示布鲁顿酪氨酸激酶在原发性中枢神经系统淋巴瘤中的关键作用。
Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.
9
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.在希腊的一家单中心，对 58 例接受伊布替尼单药治疗的 CLL 患者的长期真实世界数据进行安全性和疗效分析。
Leuk Lymphoma. 2019 Dec;60(12):2939-2945. doi: 10.1080/10428194.2019.1620944. Epub 2019 Jun 11.
10
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.伊布替尼治疗复发/难治性慢性淋巴细胞白血病的老年患者：法国71例患者的真实世界经验：法国创新白血病组织（FILO）组的一项研究
Am J Hematol. 2017 Jun;92(6):E105-E107. doi: 10.1002/ajh.24715. Epub 2017 Apr 29.
引用本文的文献
1
Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing.提高新诊断的大B细胞淋巴瘤患者的治愈率：针对临床实验室检测所定义的高危病理亚组的靶向治疗。
Cancers (Basel). 2024 Dec 24;17(1):18. doi: 10.3390/cancers17010018.
2
Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis.伊布替尼单药治疗或联合治疗复发/难治性弥漫性大B细胞淋巴瘤（R/R DLBCL）的疗效和安全性：一项系统评价和荟萃分析。
Am J Ther. 2025;32(1):e5-e16. doi: 10.1097/MJT.0000000000001831. Epub 2024 Oct 16.
3
A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia.一名95岁的患者患有高级别B细胞淋巴瘤合并毛细胞白血病。
Leuk Res Rep. 2024 Mar 24;21:100457. doi: 10.1016/j.lrr.2024.100457. eCollection 2024.
4
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.布鲁顿酪氨酸激酶抑制剂治疗B细胞恶性肿瘤中国专家共识
Exp Hematol Oncol. 2023 Oct 16;12(1):92. doi: 10.1186/s40164-023-00448-5.
5
Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment.弥漫性大B细胞淋巴瘤及其肿瘤微环境的分子诊断综述
Diagnostics (Basel). 2022 Apr 27;12(5):1087. doi: 10.3390/diagnostics12051087.
6
Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.基于泊马度胺的挽救性免疫化疗作为弥漫性大 B 细胞淋巴瘤三线或以上治疗的真实世界经验。
Ann Hematol. 2022 Feb;101(2):349-358. doi: 10.1007/s00277-021-04711-9. Epub 2021 Nov 11.
7
Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.协同 miRNA 依赖性的 PTEN 调控导致 B 细胞淋巴瘤恶性肿瘤对 BTK 抑制的耐药性。
Cell Death Dis. 2021 Nov 8;12(11):1061. doi: 10.1038/s41419-021-04353-9.
8
Radiotherapy for Non-Hodgkin Lymphomas.非霍奇金淋巴瘤的放射治疗。
Cancer J. 2020 May/Jun;26(3):217-230. doi: 10.1097/PPO.0000000000000453.
9
Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?嵌合抗原受体工程化T细胞时代难治性弥漫性大B细胞淋巴瘤的细胞免疫治疗：异基因移植仍有作用吗？
Biol Blood Marrow Transplant. 2020 Apr;26(4):e77-e85. doi: 10.1016/j.bbmt.2019.12.771. Epub 2020 Jan 7.
本文引用的文献
1
Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas.比较不同评估技术，包括免疫组化染色的数字图像分析，用于侵袭性 B 细胞淋巴瘤中 MYC 蛋白的表达。
Hum Pathol. 2019 Jan;83:124-132. doi: 10.1016/j.humpath.2018.08.019. Epub 2018 Aug 30.
2
Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.MYC和BCL2的共表达预示着接受R-ICE方案治疗且有移植意向的复发/难治性弥漫性大B细胞淋巴瘤患者预后较差。
Ther Adv Hematol. 2018 Apr;9(4):81-87. doi: 10.1177/2040620718759249. Epub 2018 Mar 29.
3
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.一项关于接受依鲁替尼治疗的复发或难治性弥漫性大B细胞淋巴瘤患者的多机构疗效分析。
Blood. 2017 Oct 5;130(14):1676-1679. doi: 10.1182/blood-2017-05-786988.
4
MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.MYC蛋白阳性弥漫性大B细胞淋巴瘤具有活化的B细胞受体信号通路特征。
Am J Surg Pathol. 2017 Apr;41(4):541-549. doi: 10.1097/PAS.0000000000000799.
5
Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.伴有MYC和BCL2高表达的弥漫性大B细胞淋巴瘤通过定量免疫荧光显示出活跃的B细胞受体信号传导的证据。
PLoS One. 2017 Feb 17;12(2):e0172364. doi: 10.1371/journal.pone.0172364. eCollection 2017.
6
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.复发或难治性双表达和双打击淋巴瘤在自体干细胞移植后的无进展生存期较差。
J Clin Oncol. 2017 Jan;35(1):24-31. doi: 10.1200/JCO.2016.68.2740. Epub 2016 Oct 24.
7
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
8
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.在弥漫性大B细胞淋巴瘤中使用依鲁替尼靶向B细胞受体信号传导
Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.
9
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.MYC/BCL2 蛋白共表达有助于激活 B 细胞型弥漫性大 B 细胞淋巴瘤的生存预后不良，并表现出高危基因表达特征：来自国际弥漫性大 B 细胞淋巴瘤利妥昔单抗-CHOP 联合方案的报告。
Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.
10
Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.定量免疫荧光显示弥漫性大 B 细胞淋巴瘤中活跃的 B 细胞受体信号的特征。
Clin Cancer Res. 2012 Nov 15;18(22):6122-35. doi: 10.1158/1078-0432.CCR-12-0397. Epub 2012 Sep 10.
Zotero 插件